This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in patients with nAMD

Imperial College Healthcare NHS Trust

nAMD

These data are from real patients. Individual results may vary.

Study design:
Retrospective observational audit evaluated outcomes in 22 treatment-naïve eyes and 93 previously treated eyes with nAMD followed up for 12 months. All eyes were initiated on or switched to EYLEA 8 mg between March 2024 and August 2025.

Treatment-naïve eyes received EYLEA 8 mg loading injections (initiated with one injection per month for three consecutive doses), followed by a T&E protocol.
Previously treated eyes with active disease despite prior treatment with other anti-VEGF agents were initiated with one injection per month for three consecutive doses of EYLEA 8 mg, followed by a T&E protocol with 4-week interval extensions. Eyes that maintained a dry macula on another anti-VEGF agent but that could not be extended beyond q8 were switched to EYLEA 8 mg T&E* without the loading phase.

Patient demographics for all patients	
Eyes, N	115
Mean age, years	79.1
Female, %	45

Treatment-naïve patients

Extended treatment intervals with EYLEA 8 mg





~3 in 5 patients
achieved a last treatment interval of **≥q12** at 12 months without recurrent disease activity (59.1%, N=13/22)

Fast drying with 3 loading doses of EYLEA 8 mg

Change in CFT over time



−149 µm
Mean change in CFT with EYLEA 8 mg (N=22)

Meaningful vision gains with EYLEA 8 mg

Change in BCVA over time†



+11.0 ETDRS letters
Mean change in BCVA with EYLEA 8 mg (N=22)

No unexpected safety signals related to EYLEA 8 mg were observed during the audit period‡

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
Figures do not show all time points analysed (after 6 months and after 9 months data are not included). Figures show whole group analyses and do not show macular scar subgroup analyses. *Intervals were not less than 8 weeks. †Values converted from logMAR. ‡One patient was not fully responsive to treatment; this patient was switched to faricimab following completion of 12 months on EYLEA 8 mg.

Abbreviations:
BCVA, best corrected visual acuity; **CFT**, central foveal thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **logMAR**, logarithm of the minimum angle of resolution; **nAMD**, neovascular age-related macular degeneration; **qX**, every X weeks; **T&E**, treat-and-extend; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_PP-EYL-GB-3034_November 2025

May 2026 | PP-EYL_8mg-GB-1034

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

nAMD

Previously treated patients

Previous anti-VEGF treatment
(N=93)



‘Wet’ vs. dry eyes prior to switch*
(N=93)



Extended treatment intervals with EYLEA 8 mg

Last treatment interval†



4.3%
≥q12 pre-switch
(N=4/93)

67.8%
≥q12 12 months after switch to EYLEA 8 mg
(N=63/93)

Vision gains
with EYLEA 8 mg

Change in BCVA over time‡



+4.5 ETDRS letters
Mean change in BCVA with EYLEA 8 mg (N=93)

Sustained fluid control
with EYLEA 8 mg

Change in CFT over time



–17 µm
Mean change in CFT with EYLEA 8 mg (N=93)

No unexpected safety signals related to EYLEA 8 mg were observed during the audit period

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
Figures do not show all time points analysed (8 weeks after third injection and after 9 months data are not included). Figures show whole group analyses and do not show macular scar subgroup analyses.
*Eyes with IRF or SRF are considered wet, those without are considered dry.
†Values may not add up to 100% owing to rounding. ‡ Values converted from logMAR.

Abbreviations:
BCVA, best corrected visual acuity; **CFT**, central foveal thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **logMAR**, logarithm of the minimum angle of resolution; **nAMD**, neovascular age-related macular degeneration; **qX**, every X weeks; **T&E**, treat-and-extend; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_PP-EYL-GB-3034_November 2025

May 2026 | PP-EYL_8mg-GB-1034

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device’s browser settings have automatic PDF download enabled.